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 Breast cancer is the most commonly diagnosed cancer among women and the second 
leading cause of cancer mortality in women (1). Obesity, an established risk factor for multiple 
cancer types including breast cancer, alters major physiological and signaling pathways involved 
in tumor growth and progression (7). Disturbances in fatty acid metabolism seen in obesity, 
including increased lipolysis and deregulated fatty acid transport, have been shown to drive breast 
cancer proliferation and progression (8, 9), and metastasis (10). Sustained obesity also causes 
dysregulation of leptin signaling, leading to leptin resistance and excess leptin production by the 
adipose tissue, increasing activation of tumor growth promoting factors in the JAK-STAT pathway 
(19, 21). CD36 and FATP1, membrane-bound fatty acid transporters, have been studied as 
potential drivers of cancer metastasis in both human and murine models. Moreover, CD36 
expression may be increased through leptin activation of STAT3, offering a potential explanation 
for increased metastasis seen in obese breast cancer patients (17). To test whether high leptin levels 
in the obese state might mediate increased CD36 expression in breast cancer cells, we treated a 
panel of human and murine breast cancer cell lines with recombinant leptin in vitro. We were 
unable to demonstrate CD36 induction by leptin treatment in murine lines and saw a heterogeneous 
response in human lines. However, we found increased expression of FATP1 in multiple metastatic 
breast cancer cell lines compared to non-metastatic lines. To understand FATP1’s role in breast 
cancer metastasis, the MMTV-Wnt1 breast cancer progression series was transduced using 
lentiviral delivery of shRNA to knockdown FATP1 gene expression. We demonstrated a selective 
reduction of cell proliferation in metastatic FATP1 knockdown cell lines, which highlights the 
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Breast Cancer Prevalence and Mortality 
 
As the second leading cause of death worldwide and with incidence and mortality rising 
rapidly, cancer is one of the largest global public health concerns (1). Breast cancer is the most 
commonly diagnosed cancer among women and the second leading cause of cancer mortality in 
women (1). Breast cancer that has disseminated beyond the primary site of growth, a process 
known as metastasis, is largely responsible for the high rates of breast cancer mortality in women, 
as stage IV metastatic breast cancer has a 5-year survival rate of only 27% (2). Metastatic cancers 
in particular are largely responsible for global cancer mortality, as 90% of all cancer mortality 
occurs only after metastasis (3). There are several hypotheses to explain, in part, the metastatic 
process, such as cancer stem cells, metabolic reprogramming, or the epithelial to mesenchymal 
transition of cells, however, there is still significant uncertainty in the characterization of the 
drivers of metastatic disease (3). And while several therapeutic approaches such as chemotherapy, 
radiation, and endocrine therapy have reduced mortality rates over the past few decades, the wide 
range of breast cancer phenotypes has limited the effectiveness of these therapeutic strategies.  
Fatty Acid Signaling and Obesity in Cancer 
A key feature of breast cancer development and metastasis are the alterations to cellular 
metabolism that help drive tumor growth and progression (4). Obesity, an established risk factor 
for multiple cancer types including breast cancer, alters major physiological and signaling 
pathways involved in tumor growth and progression (5). The prevalence of obesity has been 
increasing rapidly, rising to 42.4% in 2018 and contributing to an increase in poor outcomes and 
cancer-related mortality in the US (6, 5).  Although the exact mechanisms linking obesity and 
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breast cancer metastasis remain unclear, one potential candidate is fatty acid signaling and 
metabolism. 
Fatty acids are critical for the survival and renewal of cancer cells (7). Disturbances in fatty 
acid metabolism seen in obesity, including increased lipolysis and deregulated fatty acid transport, 
have been shown to drive breast cancer proliferation and progression (8, 9), and metastasis (10). 
Proteins central to lipid transport include the Fatty Acid Binding Protein (FABP) family, the Fatty 
Acid Transport Protein (FATP) family, and the scavenger receptor CD36 (7). CD36, in particular, 
has been studied as a potential driver of cancer metastasis in both human and murine models. Table 
1 summarizes previous studies on the role of CD36 in various carcinomas. In ovarian cancer, CD36 
expression induced by adipocyte co-culture was shown to drive cancer cell progression and 
metastasis (11). Additionally, CD36 knockout cells showed reduced metastatic ability in both 
Luminal A breast cancer and melanoma (12). Furthermore, in multiple subtypes of breast cancer, 
patients with metastatic disease had a higher fraction of CD36-positive circulating tumor cells 
(13). In addition to CD36, previous in vitro work has shown high expression of FABP4 to be 
implicated in enhancing expression of genes that promote cell growth and migration in ovarian 
cancer (14); additionally, knockdown of FABP4 in vivo led to lower migration and invasion in 
murine ovarian cancer models (14). However, the optimal mechanisms for targeting this system to 







Table 1: Impact of Varying CD36 Expression on Multiple Cancer Types  
Cancer Type Finding Citation 
Breast Cancer, Multiple Subtypes 
Patients with metastatic disease had a higher 
fraction of circulating CD36-positive tumor 
cells 
Pizon et al. 2018 (15) 
Ovarian Cancer 
CD36 expression induced by adipocyte co-
culture drives cancer cell progression and 
metastasis 
Ladanyi et al. 2018 (11) 
Luminal A Breast Cancer CD36-depleted cells showed decreased cell proliferation Zhao et al. 2017 (16) 
Oral Squamous Cell Carcinoma CD36+ cells initiate and promote metastasis; Anti-CD36 therapy reduces metastasis Pascual et al. 2016 (12) 
Luminal A Breast Cancer CD36 knockout cells showed reduced metastatic ability Pascual et al. 2016 (12) 
Melanoma CD36 knockout cells showed reduced metastatic ability Pascual et al. 2016 (12) 
Hepatocellular Carcinoma Fatty acid treatment supports pro-metastatic gene expression via CD36  Nath et al. 2015 (17)
 
Glioblastoma CD36 drives renewal of cancer stem cells and cancer progression Hale et al. 2014 (18)
 
 
Leptin Signaling, Obesity, and Cancer 
Leptin, a peptide hormone, when bound to its ObR receptor on the cell membrane activates 
a JAK-STAT signaling cascade, inducing a number of physiological changes associated with 
energy balance that promote tumor growth (19). Recent work in our group, as well as by others, 
has shown the potential for leptin to induce invasion and metastasis in mouse models of breast 
cancer (20). Sustained obesity causes dysregulation of leptin signaling, leading to leptin resistance 
and excess leptin production by the adipose tissue, thus increasing activation of proangiogenic and 
other tumor growth promoting factors in the JAK-STAT pathway (21, 19).  Additionally, leptin 
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has been shown to induce epithelial-to-mesenchymal transition (EMT) via the ERK signaling 
pathway, demonstrating another potential mechanism through which leptin may act to increase 
metastatic potential among various cancer types (22).  Despite substantial evidence of leptin’s role 
in activating various oncogenic pathways including angiogenesis, proliferation, and epithelial-
mesenchymal transition, current research is still limited in describing leptin’s role in the obesity-
cancer link (23).  
Leptin and Fatty Acid Metabolism 
Although leptin may directly modulate cancer growth and progression through activation 
of the JAK-STAT pathway, there is growing evidence of leptin’s role in modulation of fatty acid 
metabolism (19). Leptin has been shown to selectively stimulate fatty acid oxidation through direct 
activation of AMP-activated protein kinase (AMPK) in skeletal muscle (24). In addition, leptin 
has also been suggested as a modulator of CD36 gene expression. Previous research has shown 
increased expression of CD36, a membrane-bound translocase involved in fatty acid uptake, 
following STAT3 induction in chronic lymphocytic leukemia (CLL) cells (25). Supporting these 
findings, an inspection of the human genomic map shows several STAT3 binding sites in the 
promoter region of CD36 (17). Furthermore, in vivo experiments have showed that CD36 is a key 
regulator in production and signaling of leptin in adipocytes (26).  Thus, we propose that CD36, 
leptin, and the interaction between them may be crucial to the link between the dysregulated lipid 




Figure 1: Proposed mechanism of leptin-induced activation of CD36 in the obese state. 
 
FATP1 and Breast Cancer Metastasis  
Although research has largely focused on CD36 as a target for modulating lipid transport 
in cancer, the FATP/SLC27A family has recently emerged as an alternative in multiple cancer 
types. Like CD36, fatty acid transport protein 1 (FATP1) is an essential fatty acid membrane 
transporter allowing uptake of long chain fatty acids into cells (7). Aberrant expression of FATP1 
has previously been seen in melanoma cancer models, with inhibition of FATP1 decreasing 
melanoma lipid uptake, invasion, and growth (27). In addition, patient data has shown that 
increased expression of FATP1 in the triple negative breast cancer subtype correlates with a 
decreased overall survival rate as well as decreased progression-free survival (7).  Unraveling 
mechanisms on the altered role of FATP1 within the context of breast cancer could help to provide 




This present study aims to further our understanding of the role of fatty acid transporters in breast 
cancer metastasis in an effort to provide future viable treatment strategies in preventing metastasis 
across multiple breast cancer subtypes. We propose to use our models of metastatic breast cancer 
in concert with lentiviral gene expression modulation to rigorously test the hypothesis that fatty 
acid transport is an important mediator in the breast cancer metastatic process. We plan to test this 
hypothesis by pursuing the following specific aims: 
Aim 1. Establish the impact of leptin treatment on fatty acid transporter expression 
in both non-metastatic and metastatic breast cancer cell lines. Baseline expression of 
fatty acid transporters in the MMTV-Wnt1 metastatic murine breast cancer series will be 
determined using microarray data and will be validated with RT-qPCR. Cell lines will then 
be treated with leptin and changes to fatty acid transporter expression will be determined 
using RT-qPCR. 
Aim 2. Modulate identified targets and establish the impact on metastatic potential in 
a metastatic breast cancer progression series.  
Modulation will be performed using knockdown of targets identified in aim 1 and 
characterizing impact on metastatic potential through migration and invasion assays. 
Knockdown of our target will be carried out using lentiviral delivery of specific shRNA. 
Knockdown of gene targets will be validated using RT-qPCR. Manipulated cells will be 







Materials and Methods 
Cell line and culture conditions 
For Aims 1 and 2, we used a metastatic progression series of four murine breast cancer cell lines, 
generated from the MMTV-Wnt1 model. Two non-metastatic breast cancer lines, E-Wnt (basal-
like, ER+) and M-Wnt (claudin-low, TNBC) were grown directly from clones taken from an 
MMTV-Wnt1 tumor as previously described (28), while two metastatic lines, metM-Wntliver, 
metM-wntLung, were derived from the liver and lung metastases following serial in vivo 
transplantation of M-Wnt cells (29). Additionally, for leptin treatment assays, we used the E0771, 
MMTV-neu, 4T1, as well as the C3Tag series M6, and leptin knockdown (OBR3) and control 
scrambled (SCR5) lines of murine metM-WntLung (30, 37). Human lines including MDA-MB-468, 
MDA-MB-231, MCF7, BT 549, and SKRB3 were also cultured. All cell lines were cultured in 
10% FBS cell culture media (RPMI 1640, (-) Phenol Red, (+) L-Glutamine, 10% FBS, 50 μg/ml 
penicillin/streptomycin, 0.2 mM L-glutamine, 0.01M HEPES buffer).  
In Vitro Leptin Treatment 
A panel of 10 mouse breast cancer cell lines with triplicate biological replicates were cultured with 
and without leptin supplementation (100 ng/mL) in 10% FBS cell culture media for 18 hours. 
Human breast cancer lines were similarly assayed for gene expression upon leptin 
supplementation. MDA-MB-231 cells were further analyzed at 1, 4, and 18 hours following leptin 
treatment. At specified timepoints, RNA was extracted for RT-qPCR gene expression analysis.  
RNA extraction and relative quantifying real-time polymerase chain reaction (RT-qPCR)  
RNA of cell lines was extracted using Omega Bio-Tek E.Z.N.A. HP Total RNA Isolation Kit 
(Omega Bio-tek, Inc, Norcross, GA). RNA concentration samples were analyzed by NanoDrop 
(Thermo Fisher Scientific, Waltham, MA) measuring at 260nm. cDNA was synthesized from RNA 
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samples using SimpliAmp Thermal Cycler (Thermo Fisher Scientific, Waltham, MA) at volume 
of 20 uL. Samples were then diluted 1:10 in RNAase-free H2O and analyzed using TaqMan 
(Thermo Fisher Scientific, Waltham, MA) and SYBR Green (Thermo Fisher Scientific, Waltham, 
MA) primers and through RT-qPCR using the ViiA 7 Real-Time PCR System (Thermo Fisher 
Scientific, Waltham, MA). Gene expression results were normalized to β-actin, and relative 
expression was calculated using ∆∆CT. Primers used in SYBR Green experiments were designed 
using PrimerBank (36). Genes analyzed included CD36, ACTB, SOCS3, FABP4, LEPR, ZEB1, 
and FATP1. 
Lentiviral shRNA knockdown of FATP1 
MMTV-Wnt1 progression series (E-Wnt, M-Wnt, Met-M-WntLung, Met M WntLiver) were seeded 
in separate 96 well plates at 7,500 cells/well. After 24 hours, cells were transduced at 52,500 
transduction units of the virus for the more concentrated wells (2x), and 26,250 transduction units 
for the 1x wells in a 96-well, using conditions determined previously: virus was added to cells kept 
in serum-free and antibiotic-free transduction medium with polybrene (10 ug/mL). After 24 hours, 
transduction medium was changed to polybrene-free and antibiotic-free Growth Medium (with 
10% serum).  After 24 hours, cells were trypsinized and expanded into a larger culture vessel with 
selection medium (containing the predetermined concentration of puromycin: 10ug/uL). Cells 
were then replaced with fresh selection medium after 24 hours. At day 7, cell lines were induced 
with shRNA expression in the experimental cells using the predetermined optimal doxycycline 
dose (1ug/mL) and then checked for transduction via TurboRFP expression 48 hours later. While 
E-Wnt and M-Wnt cells were selected using only puromycin selection, Met-M-WntLung and Met 
M WntLiver cells were required to undergo FACS for a pure population of RFP-positive cells using 




Cells were seeded in 96-well plates at a density of 2,000 cells per well and incubated for 24 hours 
in 10% FBS cell culture media. Wells were replaced with 10% FBS cell culture media and 10% 
FBS cell culture media with doxycycline in ethanol (1ug/mL). Cells were incubated for 48 hours 
and stained with 100uL of MTT solution (1:10 dilution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide and 2% cell culture media) for an additional 2 hours, covered in foil 
and incubated at 37°C. MTT reagent was removed, 100uL of DMSO was added, and the plates 
were put on a plate shaker for 10 minutes. Cell viability was recorded using the Cytation 5 Cell 
Imaging Reader (BioTek Winooski, VT) at 595 and 690nm. 
Statistical Analysis 






CD36 is a Fatty Acid Transporter with Therapeutic Potential in Cancer 
 
Given previous work regarding the role of CD36 in cancer metastasis in multiple human 
and murine cancer models, we analyzed publicly available data from The Cancer Genome Atlas 
(TCGA) to evaluate the relationship between CD36 expression and survival rates in a number of 
cancers (31). Although not statistically significant in breast cancer, TCGA data revealed a trend of 
higher CD36 expression leading to lower survival in cancer types (Figure 2).    
  
 
Figure 2: Higher CD36 expression is associated with reduced survival rates in several human 
cancers. TCGA was queried for clinical survival data for patients in the top and bottom quartile 
of CD36 gene expression. Kaplan-Meier survival curves were plotted for multiple cancer types 
including A: Bladder Cancer (p=0.0314), B: Breast Cancer (p=0.117), C: Colon Cancer (p=0.08), 






Following our findings in TCGA survival data, we decided to probe existing microarray gene 
expression databases to assess CD36 expression levels in several breast cancer cell lines and found 
higher expression of CD36 in the metastatic MetM-wntLiver relative to M-Wnt (probe 1: q=0.039, 
probe 2: q=0.24). Based on variability in expression of CD36, we decided to further evaluate CD36 





















Figure 3 A-B: Existing Microarray of two probes (A: P375146, B: P375138) of CD36 gene 
expression in Wnt progression series and E0771 cell lines. MetMwntLiver cell line showed higher 
expression compared to baseline M-Wnt gene expression levels. All comparisons were adjusted 
for multiple comparisons.  
 
CD36 Is Not Detectable in MMTV-Wnt1 Progression Series, and is Expressed 
Heterogeneously in Human Breast Cancer Lines 
Given previous work on aberrant expression of CD36 in driving metastatic cancer models, 














































































cancer model: the MMTV-Wnt1 (Wnt) series (MetMwntLiver, metMwntLung, M-Wnt, and E-Wnt). 
Using RT-qPCR we could not find detectable expression levels of CD36 in the Wnt series, using 
both a SYBR Green-based method with primers validated on PrimerBank (36) as well as 
commercially validated TaqMan CD36 primer/probe assay (Figure 4A). Following our inability 
to detect CD36 in the Wnt series, we looked at mice macrophages to validate whether the SYBR 
Green and Taq-Man primers for CD36 were functioning as intended, or if there was a separate 
issue in our gene expression pipeline. We detected CD36 at appropriate levels in mice 
macrophages, with an average Ct value of ~20 and ∆Ct values of 3.25 when compared to robustly 
expressed housekeeping genes (Figure 4B).  
Unable to initially detect CD36 in the Wnt progression series, we moved to establish 
baseline expression of CD36 across human in vitro breast cancer lines. Using RT-qPCR we found 
detectable, but heterogeneous expression of CD36 among MDA-MB-468, MDA-MB-231, MCF-




























































































Figure 4 A-B: Baseline RNA levels of CD36 across Wnt series. RNA expression of CD36 
was not able to be detected in the murine Wnt Progression series. n.d.; Not Detected. Figure 3B 








































Figure 5: Baseline RNA levels of CD36 across 
human breast cancer lines. Heterogeneous 
expression was observed among human breast 
cancer lines with SKBR3 and MDA-MB-231 
showing higher expression levels compared to 
MCF-7 and BT 549 lines. Cell lines were seeded 
in triplicates and relative expression was 
normalized to MCF7 expression levels. 
(Comparisons between cell lines vs MCF7 for 
each gene was made using a one-way ANOVA 
with Dunnett’s Correction *; p<0.05). 
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Leptin Supplementation Does Not Induce Consistent Gene Expression Responses in Human 
or Murine Breast Cancer Lines 
We pulled a genomic map from UCSC looking at the CD36 gene in a human normal-like 
breast line, MCF10A (25). Probing for STAT3 binding sites, we found multiple sets of STAT3 
binding sites along the promoter region of CD36 (Figure 6), supporting previous findings on 
leptin’s demonstrated ability to act as an inducer for CD36 expression in cancer lines and normal 
tissue (25). Additionally, when we analyzed TCGA survival data (Figure 7), we found that higher 
leptin receptor expression was associated with significantly lowered survival rates in breast cancer 
(31). Given these findings, in addition to leptin’s role as an important mediator of cancer metastasis 
(20), we moved to treat both murine and human lines with leptin and analyze whether leptin 
treatment leads to induction of CD36. We treated an array of human and murine breast cancer lines 
with leptin at a concentration of 100 ng/mL that was determined based on the highest quartile of 
serum leptin levels seen in obese individuals in order to replicate physiological leptin levels for in 
vitro analysis (38). Following an 18-hour leptin treatment, we analyzed relative RNA expression 
among human and murine breast cancer lines. Following leptin treatment, CD36 could still not be 
detected in murine lines (Figure 8A). In human cell lines tested, we found that MDA-MB-231 cells 
increased CD36 RNA expression when treated with leptin for 18 hours, while no other cell lines 






Figure 6: Map of CD36 Genomic Region with STAT3 binding sites identified in a human 
MCF10A cell line series. Genomic map reveals multiple STAT3 binding sites within the genomic 
promoter region of CD36 (32). 
 
 
Figure 7: Higher Leptin receptor expression is associated with reduced survival rates in 
breast and ovarian cancers. TCGA was queried for clinical survival data for patients in the top 
and bottom quartile of LEPR gene expression. Kaplan-Meier survival curves were plotted for 
multiple cancer types including A: Bladder Cancer (p=0.033, B: Breast Cancer (p=0.04), C: Colon 











Figure 8 A-B: Relative Expression Levels After 18 Hour leptin supplementation. Cell lines 
were seeded in triplicate 10-cm plates and were supplemented with leptin (100 ng/mL) in 10% 
FBS culture media for 18 hours before being analyzed for RNA expression using RT-qPCR. Each 
leptin supplemented cell line was normalized to their own baseline RNA expression levels. MDA- 
MB-231 (p=0.044) showed higher expression with leptin treatment while MCF7, BT-549, BT-
474, and MDA-468 all showed significantly lower expression of CD36 after 18 hours of leptin 
supplementation. (T-tests were conducted between cell line and its matched samples treated with 
leptin *; p<0.05).  
 
Although leptin treatment seemed to decrease expression of CD36 in many of the human 
cell lines tested, we did see significantly increased expression in MD-MB-231. As this is a highly 
metastatic TNBC human cell line, we decided to move forward and compare leptin treatment at 1, 
4, and 18-hour time points to analyze temporal expression of CD36 to determine whether we were 
simply missing peak expression levels. Since many of the cell lines showed decreased expression 
of CD36, we believed at 18 hours there may be negative feedback in CD36 expression.  Because 
of this, we decided to analyze SOCS3 expression as well. SOCS3 serves as a downstream 
regulating protein inhibiting JAK and pSTAT3 activation and is a classic marker of leptin signaling 
axis activation that acts to negatively regulate the system (19). As a result, we expected to see an 



































































































pathway. However, leptin supplementation at 1, 4, and 18 hours did not significantly alter SOCS3 











Figure 9:  Expression levels of CD36 and SOCS3 at 1, 4, 18-hour time points. MDA MB 231 
were seeded in triplicates for each duration and RNA expression levels were determined and 
normalized to baseline MDA MB 231 levels. Statistical testing revealed non-significant changes 
to CD36 expression and SOCS3 expression. (One-way ANOVA with Dunnett’s correction for 
multiple comparisons was used for data analysis of multiple groups *; p<0.05). 
 
MDA-MB-231 did not show significant increase in CD36 expression at different durations 
of leptin treatments. Due to inconsistent RNA expression of CD36 under leptin treatment, we 
wanted to analyze RNA expressions of other fatty acid transporting genes, including FATP1 and 
FABP4. Similar to CD36, FATP1 contains STAT3 binding domains in its promoter region (25), 
and like CD36, FATP1 protein content increased in response to leptin treatment in HL-1 
cardiomyocytes (34).  FABP4 has been implicated in various carcinomas and was found previously 
to reduce leptin signaling in mice adipocytes (35). Additionally, we looked at expression of leptin 
receptor (LEPR) as well as ZEB1, a marker for EMT, because of previous work showing leptin’s 
ability in driving EMT transition in cancer models (22). To better understand the effects of leptin 
























including the MMTV-Wnt1 progression series (Figure 10), as well as MMTV-neu (mouse-
equivalent HER2) and the highly metastatic 4T1 (Figure 11). We found a heterogeneous 
expression response of both FABP4 and FATP1, as well as LEPR and ZEB1 when treated with 
leptin. We concluded that leptin supplementation at 100 ng/mL did not reliably induce fatty acid 



















Figure 10: Differential expression with and without leptin supplementation of FABP4, 
FATP1, LEPR, and ZEB1 across MMTV-Wnt1 progression series. Cell lines showed 
heterogeneous expression with leptin supplementation across subtype and metastatic potential. (T-



























































































































































































FATP1 is Upregulated in Metastatic compared to Non-Metastatic Cell Lines  
 
Revisiting our microarray analysis of breast cancer cell lines, we identified FATP1 as 
significantly upregulated in both of our metM-Wnt lines compared to the non-metastatic M-Wnt. 
Importantly, this relationship also held when comparing the non-metastatic M-Wnt to the 
metastatic E0771 (Figure 12). To validate our findings from the microarray, we cultured the Wnt 










































































































































Figure 11: Differential expression with and without leptin supplementation of FABP4, 
FATP1, LEPR, and ZEB1 across a panel of murine cell lines. Cell lines showed 
heterogeneous expression with leptin supplementation across subtype and metastatic potential. 
E0771 showed increased expression of FATP1 after leptin treatment (p=0.036). (T-tests were 
conducted between cell line and its matched samples treated with leptin *; p<0.05).  
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in order to have two non-metastatic lines for comparisons. We isolated RNA from these cell lines 
to analyze FATP1 expression via RT-qPCR, and confirmed that FATP1 expression was elevated 












Figure 12: Existing Microarray of two probes (A: P199905, B: P117477) of FATP1 gene 
expression MMTV-Wnt1 progression series and E0771 cell lines. MetMwntLiver and 
metMwntLung cell lines showed higher expression compared to baseline M-Wnt gene expression 






































































































Figure 13: Baseline RNA levels of FATP1 across in vitro MMTV-Wnt1 progression series. 
Each cell line was normalized to M-Wnt gene expression levels and 3 biological replicates were 
cultured 24 hours apart to determine baseline gene expression level. MetMwntLung showed higher 
expression FATP1 compared to M-Wnt (p=0.0642) and MetMwntLiver showed significantly higher 
expression of baseline FATP1 (p=0.0023). Comparisons between cell lines vs M-Wnt was made 
using a one-way ANOVA with Dunnett’s Correction *; p<0.05).  
 
Successful Inducible Knockdown of FATP1 Does Not Change Baseline Expression  
 After validating higher expression of FATP1 in the metMwntLiver and metMwntLung lines, 
we decided to modulate FATP1 to further investigate its role in breast cancer metastasis. We 
knocked down FATP1 using lentiviral delivery of a Tet-On/Off inducible shRNA in the Wnt 
progression series: metMwntLiver, metMwntLung, M-Wnt, and E-Wnt. Knockdown of FATP1 was 
verified through RT-qPCR (Figure 14 A-B). Noticeably, while M-Wnt, metMwntLiver, and 
metMwntLung cells showed similar knockdown with either a 1x or 2x dose of lentivirus, the E-Wnt 
cell line showed improved knockdown with the 2x dose of virus. Additionally, we analyzed 
expression of FATP1 in Wnt series that received lentiviral transduction in the absence of 










































able to confirm that viral transduction did not alter baseline expression in non-induced cells, and 
MetMwntLiver, metMwntLung displayed significantly higher expression of FATP1 when compared 
to the non-metastatic M-Wnt and E-Wnt lines (Figure 14C). Following validation of FATP1 
knockdown and results showing normal expression of FATP1 in the absence of shRNA induction, 
we began cell phenotyping assays to determine the effect of FATP1 modulation on metastatic 














































































































Figure 14: Knockdown of FATP1 Gene 
Expression. Cell lines were induced with shRNA 
expression in experimental cells using 
doxycycline (1ug/mL) for 48 hours and then 
isolated for RNA. Knockdown for M-Wnt, 
MetMwntLung, and metMwntLiver (A) demonstrated 
similar knockdown regardless of viral dose, while 
E-Wnts showed increased knockdown with 
increased dose (B). Viral transduction in the Wnt 
progression series did not alter baseline expression 
(C), and MetMwntLiver, metMwntLung displayed 
significantly higher expression of FATP1 when 




FATP1 Knockdown Decreases Proliferation Selectively in Metastatic Cell Lines  
 After confirming knockdown of FATP1 using lentiviral delivery of shRNA, we wanted to 
determine the impact of FATP1 knockdown on cell proliferation. To accomplish this, we used 
MTT cell proliferation assays (Figure 15). Cell proliferation was significantly reduced in the 
metMwntLung cells following FATP1 knockdown. Additionally, while non-significant, cell 
viability was trending down in the metMwntLiver FATP1 knockdown (p=0.0685) and interestingly 
was significantly increased in the M-Wnt line following FATP1 knockdown. Although these 
findings are promising, further metastatic assays need to be conducted to better characterize 










Figure 15: Relative Expression of Cell Proliferation in FATP1 Induced Knockdown. Cells 
were seeded in 96 well plates for 72 hours. Knockdown lines received dose of doxycycline 
(1ug/mL) 24 hours after seeding and cell proliferation was determined after 48 hours. Cell 
proliferation rates were normalized to each non-induced cell line. MetMwntLung showed significant 
reductions in cell proliferation (p=0.003) and metMwntLiver showed slight reduction in cell 
proliferation, but not statistically significant (p=0.0685). (T-tests were conducted between cell line 















































An emerging mechanism integral to the process of breast cancer metastasis is altered lipid 
metabolism, which is typically exacerbated in the obese state. While obesity has been recognized 
as a risk factor for breast cancer metastasis, the relationship between the two remains unclear (29). 
Leptin, when elevated in obesity, has been shown to be an important mediator in altering lipid 
metabolism and fatty acid transport (34). We aimed to further our understanding of the altered role 
of fatty acid transporters seen in the pro-metastatic environment of breast cancer, particularly in 
the leptin-high obese context. It was discovered that higher CD36 expression was associated with 
reduced survival rates in breast cancer from TCGA data sets (24). After probing existing 
microarrays of CD36, increased expression of the metastatic MetMwntLiver line was discovered 
compared to the non-metastatic M-Wnt. Because of this, in addition to multiple previous studies 
showing the role of CD36 in various human and murine carcinomas (Table 1), we decided to 
further probe the role that CD36 might play in breast cancer metastasis.  
Initial RT-qPCR runs using TaqMan and SYBR Green primers found on PrimerBank (36) 
could not find detectable levels of CD36 gene expression in the MMTV-Wnt1 progression series. 
When we characterized a panel of human breast cancer cell lines, we found that the metastatic, 
basal-like MDA-MB-231 cells expressed higher levels of CD36 than the non-metastatic, luminal 
MCF7 cells. Given leptin’s known role in fatty acid metabolism and obesity, as well as its ability 
to activate the transcription factor STAT3, we wanted to test whether leptin could induce 
expression of CD36 in our breast cancer cell lines. We utilized the UCSC Genome Database and 
found that the promoter region of CD36 contained multiple STAT3 binding sites in the human 
breast epithelial cell line MCF10A (32). Given TCGA data sets on decreased survival with higher 
expression of both CD36 and LepR, genomic data showing STAT3 binding sites in breast 
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epithelial cell lines, as well as experimental data in other cell types showing induction of CD36 
via STAT3, we began supplementing cell lines with leptin (100 ng/mL) for 18 hours in hopes to 
induce the JAK-STAT3 signaling pathway and subsequently increase CD36 expression (25).  
Following leptin supplementation in human cell lines, the more aggressive and invasive 
MDA-MB-231 were found to have significantly higher expression of CD36 and so we focused in 
on MDA-MB-231 cells to observe changes in RNA expression over time. In addition to CD36, 
SOCS3 expression was measured. SOCS3 serves as a downstream regulating factor of the JAK-
STAT pathway preventing phosphorylation and activation of STAT3 (19). Since multiple human 
cell lines analyzed revealed reduction in CD36 expression following leptin treatment, we believed 
negative feedback of the JAK-STAT pathway through SOCS3 may have resulted in decreased 
CD36 expression when treated for 18 hours, so we selected 1, 4, and 18-hour time points of leptin 
treatment for further analysis of CD36 induction. MDA-MB-231 cells displayed no significant 
changes in expression of either CD36 or SOCS3 at the 1, 4, and 18-hour time points of leptin 
supplementation. Cells receiving leptin treatment showed no morphological changes or changes 
in visible cell death (data not shown), and data displayed was relative expression normalized to 
the reference gene, accounting for potential differences in cell count between conditions. Further 
experiments need to be conducted to determine whether the leptin dosage used was inadequate or 
not sustained long enough to induce the JAK-STAT3 pathway response. Using these and other 
measures could potentially better induce the JAK-STAT pathway and thus provide clearer insight 
into the relationship between CD36 and leptin, but are outside the scope of this research. 
After validating that we could detect CD36 expression in mice macrophages, we decided 
to also look at a panel of murine breast cancer lines with leptin supplementation in hopes of 
inducing detectable expression of CD36 in the MMTV-Wnt1 progression series as well as a panel 
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of murine lines (Figure 7). Although we were unable to induce CD36 expression through leptin in 
murine breast cancer lines, we evaluated expression of leptin receptor (LEPR), as well as an EMT 
marker ZEB1 previously shown to be increased in lung cancer cells induced by leptin in the ERK 
signaling pathway (22). Moreover, we looked at expression of FATP1 and FABP4, both previously 
implicated in cancer progression and metastasis, with FATP1, in particular, linked to higher leptin 
concentrations in HL-1 cardiomyocytes (34). Leptin supplementation did not induce higher 
expressions of either FATP1 or FABP4 in the majority of cell lines. E0771, however, did show 
higher expression of FATP1 when treated with leptin. Interestingly, the panel of murine breast 
cancer lines also did not show an increase in either LEPR or ZEB1 following leptin treatment, 
further indicating that our leptin supplementation did not seem to activate the JAK-STAT pathway.  
Following our issues with reproducibly measuring CD36 expression and leptin signaling, 
we revisited our microarray analysis of fatty acid transporters and identified FATP1 as a potential 
mediator of pro-metastatic behavior in our Wnt progression series.  In addition, the metastatic 
E0771 (a cell line derived from a spontaneous adenocarcinoma in a C57Bl/6 mouse) had increased 
FATP1 expression compared to the non-metastatic M-Wnt. Data from TCGA similarly showed 
decreased survival rate in patients whose breast tumors had increased expression of FATP1 (7).  
Given this data, in addition to work in melanoma showing that FATP1 deletion reduces invasion 
and growth (9), we sought to unravel FATP1’s role in breast cancer metastasis. In accordance with 
the microarray, we were able to confirm an increase in the metMwntLiver and metMwntLung FATP1 
expression when compared to the non-metastatic M-Wnt. Additionally, we included the E-Wnt 
cell line, an epithelial, non-metastatic breast cancer line which also showed low FATP1 expression 
when compared to the metastatic lines.  
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After confirming data that FATP1 was upregulated in several metastatic vs nonmetastatic 
cell lines, we modulated FATP1 to establish a better understanding of its role in cancer metastasis, 
using lentiviral transduction to induce knockdown of FATP1. We were able to successfully 
knockdown FATP1 under two different sets of viral doses for the M-Wnt, MetMwntLiver and 
metMwntLung. E-Wnt cells received same viral doses but showed partial knockdown of FATP1 
through viral transduction, which may be partly due to their epithelial-like characteristic, as these 
cells grow in sheets and theoretically display less available surface area than the other more 
mesenchymal-like lines. One option to improve transduction in the future could be a lentiviral 
spinfection, increasing contact surfaces between viral particles and the epithelial cells. As a result 
of a lack of incomplete knockdown of FATP1 in the E-Wnts, we moved to just look at M-Wnt, 
metMwntLiver and metMwntLung for our in vitro assays.  
MTT assays revealed an association of decreased cell proliferation following FATP1 
knockdown in metastatic cell lines. metMwntLiver and metMwntLung induced FATP1 KD cells 
showed reductions in cell proliferation compared to control cells that were not induced. 
Knockdown of FATP1 in metMwntLung cells particularly showed significant reduction in cell 
proliferation compared to control metMwntLung cells. Interestingly, FATP1 KD M-Wnt cells 
seemed to actually slightly increase in viability compared to non-induced controls. Previous use 
of pharmacological inhibitors of FATP1 on human TNBC cell lines concur with our results with 
decreased cell proliferation, showing promise for FATP1 as an important therapeutic target (7).  
Limitations to this finding include the fact that only two replicates were assayed, and additional 
replicates are needed to confirm MTT results of decreased proliferation in metastatic lines as well 
as moderate increases in viability in non-metastatic M-Wnt.  
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While these studies have shown clear potential for knockdown of FATP1 to decrease 
aspects of cancer metastasis including invasion and aggressiveness, multiple assays still need to 
be conducted to reveal FATP1’s full impact on breast cancer metastasis. Future directions include 
analysis of invasion and migration potential, as well as additional experiments analyzing metabolic 
rates at baseline and in the presence of fatty acids.  Furthermore, in vivo mouse models including 
primary tumor injections or tail vein assays could more effectively reveal the role that FATP1 
plays in cancer metastasis, a complicated, multi-step process involving multiple cell types at 
several sites in the body. A more complete understanding of the effects of FATP1’s modulation 
on metastatic potential may allow for novel interventions and more effective treatment strategies 







 This study was not able to reliably detect expression of CD36 in murine breast cancer cell 
lins, nor could we induce CD36 expression following leptin treatment in either human or murine 
breast cancer cell lines. Murine and human lines experienced heterogeneous expression of multiple 
fatty acid transporting genes upon leptin treatment. FATP1 showed significantly increased 
expression in multiple murine metastatic cell lines compared to non-metastatic lines. In addition, 
reduction of cell proliferation in metastatic FATP1 knockdown cell lines shows potential for 
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